LYRA vs. DXR, TMDIF, VVOS, NEPH, MODD, POCI, NMTC, PYPD, COCH, and DRIO
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Daxor (DXR), Titan Medical (TMDIF), Vivos Therapeutics (VVOS), Nephros (NEPH), Modular Medical (MODD), Precision Optics (POCI), NeuroOne Medical Technologies (NMTC), PolyPid (PYPD), Envoy Medical (COCH), and DarioHealth (DRIO). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs. Its Competitors
Daxor (NASDAQ:DXR) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.
In the previous week, Lyra Therapeutics had 5 more articles in the media than Daxor. MarketBeat recorded 5 mentions for Lyra Therapeutics and 0 mentions for Daxor. Daxor's average media sentiment score of 0.00 beat Lyra Therapeutics' score of -0.10 indicating that Daxor is being referred to more favorably in the media.
Daxor has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
1.3% of Daxor shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 59.5% of Daxor shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Daxor currently has a consensus target price of $25.00, suggesting a potential upside of 177.78%. Lyra Therapeutics has a consensus target price of $100.00, suggesting a potential upside of 1,165.82%. Given Lyra Therapeutics' higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than Daxor.
Daxor has higher earnings, but lower revenue than Lyra Therapeutics.
Daxor has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,711.39%. Daxor's return on equity of 0.00% beat Lyra Therapeutics' return on equity.
Summary
Daxor beats Lyra Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 7/19/2025 by MarketBeat.com Staff
